<DOC>
	<DOCNO>NCT02577107</DOCNO>
	<brief_summary>This prospective , randomize , open label study enroll patient neovascular AMD naïve anti-VEGF therapy receive intravitreal anti-VEGF therapy previous 3 month . Patients randomize two treatment arm 3 month : - Study arm 1 : Three monthly injection 0.5mg Ranibizumab - Study arm 2 : Three monthly injection 0.5mg Conbercept Blood sample ( plasma/serum ) collect baseline ( pre-dose ) , 3h post-injections day 1 , 3 , 7 28 , follow dos 1 3 PK systemic VEGF analysis . The lab staff blind treatment allocation . Plasma VEGF concentration measure blinded laboratory use Quantikine® ELISA kit . Serum ranibizumab conbercept concentration determine use validate ELISA assay . The study divide 2 stage : 1st initial feasibility stage 6 patient per arm ( 12 patient total ) verify SD sample size justification 2nd stage confirm finding justify sample size .</brief_summary>
	<brief_title>Head Head Study Anti-VEGF Treatment .</brief_title>
	<detailed_description>Efficacy assessment , BCVA measure ETDRS Optical Coherence Tomography Colour fundus photography fluorescein angiography</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Endothelial Growth Factors</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>1 . Written informed consent must obtain assessment perform . 2 . Male female patient ≥ 50 year age . 3 . Subfoveal CNV secondary nAMD . 4 . BCVA score must 73 24 letter measure ETDRS chart For eye 1 . Any active periocular ocular infection inflammation 2 . Uncontrolled glaucoma 3 . Neovascularization iris neovascular glaucoma . For study eye 4 . Choroidal neovascularization cause wet AMD 5 . Ocular disorder present may confound interpretation study result , 6 . Previous treatment verteporfin PDT ( Visudyne® ) , externalbeam radiation therapy , focal laser photocoagulation , vitrectomy , submacular surgery , transpupillary thermotherapy . 7 . Structural damage within 0.5 disc diameter center macula 8 . Atrophy fibrosis involve center fovea . 9 . Inability obtain require lab report . Ocular medical history 10 . History intravitreal injection antiVEGF drug within 3 month . Exclusion criterion systemic medical condition treatment 11 . Any type systemic disease treatment 12 . Any patient diagnose tumor . 13 . Stroke myocardial infarction le 3 month . 14 . Known hypersensitivity indocyanine green , fluorescein , component investigational drug formulation . 15 . Use systemic antiVEGF drug within 6 month . Exclusion criteria patient 16 . Patients participate investigational drug study within 60 day . 17 . Pregnant nursing ( lactate ) woman . 18 . Inability comply study followup procedure .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Age-related macular degeneration ,</keyword>
	<keyword>ranibizumab ,</keyword>
	<keyword>conbercept ,</keyword>
	<keyword>plasma VEGF</keyword>
	<keyword>PK</keyword>
</DOC>